EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer

Zachary A Schaaf iD, Shu Ning, Amy R Leslie, Masuda Sharifi, Xianrui Han, Cameron Armstrong, Wei Lou, Alan P Lombard, Chengfei Liu iD, Allen C Gao

Cancers · 03.11.2023 · 15 (21) · 5273

DOI: 10.3390/cancers15215273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 03.11.2023. Verfasst von Zachary A Schaaf und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, BLRD VA, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current common treatments for castration-resistant prostate cancer (CRPC) typically belong to one of three major categories: next-generation anti-androgen therapies (NGAT) including enzalutamide, abiraterone acetate, apalutamide, and darolutamide; taxane therapy represented by docetaxel; and PARP inhibitors (PARPi) like olaparib. Although these treatments have shown efficacy and have improved outcomes for many patients, some do not survive due to the emergence of therapeutic resistance. The clinical landscape is further complicated by limited knowledge about how the sequence of treatments impacts the development of therapeutic cross-resistance in CRPC. We have developed multiple CRPC models of acquired therapeutic resistance cell sublines from C4-2B cells. These include C4-2B MDVR, C4-2B AbiR, C4-2B ApaR, C4-2B DaroR, TaxR, and 2B-olapR, which are resistant to enzalutamide, abiraterone, apalutamide, darolutamide, docetaxel, and olaparib, respectively. These models are instrumental for analyzing gene expression and assessing responses to various treatments. Our findings reveal distinct cross-resistance characteristics among NGAT-resistant cell sublines. Specifically, resistance to enzalutamide induces resistance to abiraterone and vice versa, while maintaining sensitivity to taxanes and olaparib. Conversely, cells with acquired resistance to docetaxel exhibit cross-resistance to both cabazitaxel and olaparib but retain sensitivity to NGATs like enzalutamide and abiraterone. OlapR cells, significantly resistant to olaparib compared to parental cells, are still responsive to NGATs and docetaxel. Moreover, OlapR models display cross-resistance to other clinically relevant PARP inhibitors, including rucaparib, niraparib, and talazoparib. RNA-sequencing analyses have revealed a complex network of altered gene expressions that influence signaling pathways, energy metabolism, and apoptotic signaling, pivotal to cancer’s evolution and progression. The data indicate that resistance mechanisms are distinct among different drug classes. Notably, NGAT-resistant sublines exhibited a significant downregulation of androgen-regulated genes, contrasting to the stable expression noted in olaparib and docetaxel-resistant sublines. These results may have clinical implications by showing that treatments of one class can be sequenced with those from another class, but caution should be taken when sequencing drugs of the same class.

Schlagwörter

Stichwörter der Autor:innen

abirateroneapalutamidecancerdarolutamidedocetaxelenzalutamideolaparibprostateresistance

Autor:innen und Institutionen

  • Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA.
  • UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
  • Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95616, USA.
  • VA Northern California Health Care System, Sacramento, CA 95655, USA.

ORCID-Profile: Zachary A Schaaf, Chengfei Liu

Förderung

  • NCI NIH HHS
  • BLRD VA
  • NIGMS NIH HHS
  • National Cancer Institute

Zitieren

APA

Schaaf, Z. A., Ning, S., Leslie, A. R., Sharifi, M., Han, X., Armstrong, C., Lou, W., Lombard, A. P., Liu, C., & Gao, A. C. (2023). Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer. Cancers, 15(21), 5273. https://doi.org/10.3390/cancers15215273

Vancouver

Schaaf ZA, Ning S, Leslie AR, Sharifi M, Han X, Armstrong C, et al. Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer. Cancers. 2023;15(21):5273. doi:10.3390/cancers15215273

BibTeX
@article{Schaaf2023,
  author = {Schaaf, Zachary A and Ning, Shu and Leslie, Amy R and Sharifi, Masuda and Han, Xianrui and Armstrong, Cameron and Lou, Wei and Lombard, Alan P and Liu, Chengfei and Gao, Allen C},
  title = {Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {21},
  pages = {5273},
  doi = {10.3390/cancers15215273}
}
Kostenlos starten →